FDA panel backs Novo's weight-loss plan with new liraglutide nod

But the recent history for weight-loss drugs suggests Saxenda is no sure bet. In 2012, Arena ($ARNA) and Vivus ($VVUS) won FDA nods for new obesity pills with similarly starry-eyed projections, but safety concerns and payer disinterest led to …





via Get Fit Bookmark http://ift.tt/1y0vBoJ

via Tumblr http://ift.tt/1tPBCy1